Bayer Pharma Aktiengesellschaft

Lead Discovery Center Gmbh

Vladimir Savic

Wilfried Schwab

Zoltán Greff

Axel Choidas

Bert Klebl

Edmund Hoppe

Don Simpson

Klaus Godl

Gerhard Müller

Joelle Le

Jackie Macritchie

Doris Hafenbradl

Christian Hartung

Thomas Herget

Alexander Backes

Andrea Missio

Birgit Zech

Matt Cotten

Jose Bravo

Ola Engkvist

John Harris

Beatrice Felber

Brad Sherborne

Achim Freisleben

Peter Habenberger

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Growing community of inventors

Belgrade, Republic of Serbia

Vladimir Savic